Skip to main content

Week In Review: Hansoh Sells Ex-China ADC Rights To GSK In $1.6 Billion Deal

Hansoh Pharma sold ex-China rights for its B7-H4 ADC to GSK in a $1.57 billion deal. Meanwhile, OrbiMed has raised $4.3 billion in commitments for three healthcare funds, including $751 million for its OrbiMed Asia V fund.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.